The risk of Hepatitis B Virus (HBV) reactivation in CML patients under TKI therapy has been reported, but there are no clear guidelines and recommendations regarding screening and monitoring of HBV in CML patients receiving TKIs and experience on Hepatitis B reactivation under CML treatment is limited.

On the initiative of Professor Dragana Milojkovic (Imperial College London, UK), the iCMLf has formed a HBV and CML Working Group to answer open research questions. This group will collect and collate global experiences of physicians treating people with CML and HBV, with the aim of developing recommendations on monitoring and treatment for HBV in patients with CML.

The iCMLf Hepatitis B virus (HBV) Screening and Management Survey is now open and we would be delighted to learn from you.

HBV Screening and Management Survey – Please share your experiences

The iCMLf Hepatitis B Virus (HBV) prophylaxis on TKI therapy survey of practice looks at:

• CML patients in clinical practice who reactivated HBV
• Screening at baseline prior to first TKI therapy
• Management of patients with past history of HBV infection
• Specific guidelines for HBV anti-viral use for CML patients on TKI therapy

Please share your experiences with us by participating in the survey here

The survey will be open until 27^th February

Thank you for supporting this important research project.

The ultimate goal is to publish findings and to develop recommendations on monitoring and treatment for HBV in CML patients for use in clinical practice.

We will keep you up to date!

If you are interested in joining the iCMLf HBV Working Group please email info@cml-foundation.org.

iCMLf HBV Working Group:

Chair, Dragana Milojkovic (UK),

Katia Pagnano (Brazil),

Qian Jiang (China),

Delphine Réa (France),

Hemant Malhotra (India),

Fausto Castagnetti (Italy), 

Giuseppe Saglio (Italy),

Salam Al Kindi (Oman), 

Mohamed Yassin (Qatar), 

Charles Chuah (Singapore), 

Jorge Cortes (USA)